Digestive Diseases and Sciences

, Volume 64, Issue 4, pp 976–984 | Cite as

Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer

  • Trevor W. ReichmanEmail author
  • Chandra S. Bhati
  • Narendra R. Battula


Liver transplantation is the definitive treatment for patients with end-stage liver disease. Liver transplantation is also the optimal treatment for patients with hepatocellular carcinoma (HCC), especially in the setting of chronic liver disease. Unfortunately, due to the worldwide shortage of organs, this treatment is not available for all patients with HCC. Strict selection criteria have been developed in order to obtain optimal results. A surgical perspective of the preoperative selection, perioperative management, and postoperative care of patients is reviewed in depth and provides an overview for obtaining optimal long-term results from liver transplantation for HCC. With rigorous selection and patient management, excellent long-term outcomes can be obtained with liver transplantation for patients with HCC.


Liver transplantation Hepatocellular cancer Outcomes 


Compliance with ethical standards

Conflict of interest

The authors of this manuscript have no conflicts of interest related to this work.


  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: Cancer J Clin. 2017;67:7–30.Google Scholar
  2. 2.
    Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.CrossRefGoogle Scholar
  3. 3.
    El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127.CrossRefGoogle Scholar
  4. 4.
    El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817–823.CrossRefGoogle Scholar
  5. 5.
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576.CrossRefGoogle Scholar
  6. 6.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: Cancer J Clin. 2018;68:7–30.Google Scholar
  7. 7.
    Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–853.CrossRefGoogle Scholar
  8. 8.
    Chapman WC, Klintmalm G, Hemming A, et al. Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified? J Am Coll Surg. 2015;220:628–637.CrossRefGoogle Scholar
  9. 9.
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699.CrossRefGoogle Scholar
  10. 10.
    Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–1403.CrossRefGoogle Scholar
  11. 11.
    Fan J, Yang GS, Fu ZR, et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. J Cancer Res Clin Oncol. 2009;135:1403–1412.CrossRefGoogle Scholar
  12. 12.
    Lee SG, Hwang S, Moon DB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transplant. 2008;14:935–945.CrossRefGoogle Scholar
  13. 13.
    Takada Y, Ito T, Ueda M, et al. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis. 2007;25:299–302.CrossRefGoogle Scholar
  14. 14.
    Toso C, Trotter J, Wei A, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transplant. 2008;14:1107–1115.CrossRefGoogle Scholar
  15. 15.
    Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85:1726–1732.CrossRefGoogle Scholar
  16. 16.
    Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.CrossRefGoogle Scholar
  17. 17.
    Hsu CY, Liu PH, Lee YH, et al. Using serum alpha-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff? PLoS ONE. 2015;10:e0118825.CrossRefGoogle Scholar
  18. 18.
    Grat M, Kornasiewicz O, Lewandowski Z, et al. Combination of morphologic criteria and alpha-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg. 2014;38:2698–2707.CrossRefGoogle Scholar
  19. 19.
    Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transplant. 2014;20:945–951.CrossRefGoogle Scholar
  20. 20.
    Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR. Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:987–999.Google Scholar
  21. 21.
    Agopian VG, Harlander-Locke M, Zarrinpar A, et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015;220:416–427.CrossRefGoogle Scholar
  22. 22.
    Halazun KJ, Najjar M, Abdelmessih RM, et al. Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story. Ann Surg. 2017;265:557–564.CrossRefGoogle Scholar
  23. 23.
    Mehta N, Heimbach J, Harnois DM, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol. 2017;3:493–500.CrossRefGoogle Scholar
  24. 24.
    Parfitt JR, Marotta P, Alghamdi M, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transplant. 2007;13:543–551.CrossRefGoogle Scholar
  25. 25.
    DuBay D, Sandroussi C, Sandhu L, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg. 2011;253:166–172.CrossRefGoogle Scholar
  26. 26.
    Sapisochin G, Goldaracena N, Laurence JM, et al. The extended toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology. 2016;64:2077.CrossRefGoogle Scholar
  27. 27.
    Lee SG. A complete treatment of adult living donor liver transplantation: a review of surgical technique and current challenges to expand indication of patients. Am J Transplant. 2015;15:17–38.CrossRefGoogle Scholar
  28. 28.
    Yao FY, Bass NM, Nikolai B, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transplant. 2002;8:873–883.CrossRefGoogle Scholar
  29. 29.
    Ishaque T, Massie AB, Bowring MG, et al. Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change. Am J Transplant. 2019;19:564–572.CrossRefGoogle Scholar
  30. 30.
    Samoylova ML, Dodge JL, Yao FY, Roberts JP. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transplant. 2014;20:937–944.CrossRefGoogle Scholar
  31. 31.
    Montalti R, Mimmo A, Rompianesi G, et al. Absence of viable HCC in the native liver is an independent protective factor of tumor recurrence after liver transplantation. Transplantation. 2014;97:220–226.CrossRefGoogle Scholar
  32. 32.
    Millonig G, Graziadei IW, Freund MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transplant. 2007;13:272–279.CrossRefGoogle Scholar
  33. 33.
    Pommergaard HC, Rostved AA, Adam R, et al. Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European liver transplant registry. Transplant Int. 2018;31:531–539.CrossRefGoogle Scholar
  34. 34.
    Lee MW, Raman SS, Asvadi NH, et al. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: a 10-year intention-to-treat analysis. Hepatology. 2017;65:1979–1990.CrossRefGoogle Scholar
  35. 35.
    Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920–1928.CrossRefGoogle Scholar
  36. 36.
    Sandroussi C, Dawson LA, Lee M, et al. Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transplant Int. 2010;23:299–306.CrossRefGoogle Scholar
  37. 37.
    Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67:92–99.CrossRefGoogle Scholar
  38. 38.
    Mohamed M, Katz AW, Tejani MA, et al. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. Adv Radiat Oncol. 2016;1:35–42.CrossRefGoogle Scholar
  39. 39.
    Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60:192–201.CrossRefGoogle Scholar
  40. 40.
    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.CrossRefGoogle Scholar
  41. 41.
    Vitale A, Volk ML, Pastorelli D, et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology. 2010;51:165–173.CrossRefGoogle Scholar
  42. 42.
    Hoffmann K, Ganten T, Gotthardtp D, et al. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients—a prospective, randomized, double-blind, phase III trial. BMC Cancer. 2015;15:392.CrossRefGoogle Scholar
  43. 43.
    Kulik L, Vouche M, Koppe S, et al. Prospective randomized pilot study of Y90 ± sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol. 2014;61:309–317.CrossRefGoogle Scholar
  44. 44.
    Sneiders D, Houwen T, Pengel LHM, Polak WG, Dor F, Hartog H. Systematic review and meta-analysis of posttransplant hepatic artery and biliary complications in patients treated with transarterial chemoembolization before liver transplantation. Transplantation. 2018;102:88–96.CrossRefGoogle Scholar
  45. 45.
    Pomfret EA, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transplant. 2010;16:262–278.CrossRefGoogle Scholar
  46. 46.
    Yao FY, Hirose R, LaBerge JM, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transplant. 2005;11:1505–1514.CrossRefGoogle Scholar
  47. 47.
    Mehta N, Guy J, Frenette CT, et al. Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within milan criteria: a multicenter study. Clin Gastroenterol Hepatol. 2018;16:955–964.CrossRefGoogle Scholar
  48. 48.
    Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968–1977.CrossRefGoogle Scholar
  49. 49.
    Kim Y, Stahl CC, Makramalla A, et al. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria. Surgery. 2017;162:1250–1258.CrossRefGoogle Scholar
  50. 50.
    Toso C, Meeberg G, Andres A, et al. Downstaging prior to liver transplantation for hepatocellular carcinoma: advisable but at the price of an increased risk of cancer recurrence—a retrospective study. Transplant Int. 2019;32:163–172.CrossRefGoogle Scholar
  51. 51.
    Man K, Ng KT, Lo CM, et al. Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases–activation of cell invasion and migration pathways. Liver Transplant. 2007;13:1669–1677.CrossRefGoogle Scholar
  52. 52.
    Croome KP, Lee DD, Burns JM, et al. The use of donation after cardiac death allografts does not increase recurrence of hepatocellular carcinoma. Am J Transplant. 2015;15:2704–2711.CrossRefGoogle Scholar
  53. 53.
    Khorsandi SE, Yip VS, Cortes M, et al. Does donation after cardiac death utilization adversely effect hepatocellular cancer survival? Transplantation. 2016;100:1916–1924.CrossRefGoogle Scholar
  54. 54.
    Battula N, Reichman TW, Amiri Y, et al. Outcomes utilizing imported liver grafts for recipients with hepatocellular carcinoma. Liver Transplant. 2017;23:299–304.CrossRefGoogle Scholar
  55. 55.
    Nagai S, Yoshida A, Facciuto M, et al. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology. 2015;61:895–904.CrossRefGoogle Scholar
  56. 56.
    Grat M, Kornasiewicz O, Lewandowski Z, et al. The impact of surgical technique on the results of liver transplantation in patients with hepatocellular carcinoma. Ann Transplant. 2013;18:448–459.CrossRefGoogle Scholar
  57. 57.
    Mangus RS, Fridell JA, Vianna RM, Cooper AB, Jones DT, Tector AJ. Use of the piggyback hepatectomy technique in liver transplant recipients with hepatocellular carcinoma. Transplantation. 2008;85:1496–1499.CrossRefGoogle Scholar
  58. 58.
    Akbulut S, Kayaalp C, Yilmaz M, et al. Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patients. World J Gastroenterol. 2013;19:1625–1631.CrossRefGoogle Scholar
  59. 59.
    Han S, Kim G, Ko JS, et al. Safety of the use of blood salvage and autotransfusion during liver transplantation for hepatocellular carcinoma. Ann Surg. 2016;264:339–343.CrossRefGoogle Scholar
  60. 60.
    Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006;1:CD005033.Google Scholar
  61. 61.
    Katz SC, Shia J, Liau KH, et al. Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg. 2009;249:617–623.CrossRefGoogle Scholar
  62. 62.
    Liu B, Teng F, Fu H, et al. Excessive intraoperative blood loss independently predicts recurrence of hepatocellular carcinoma after liver transplantation. BMC Gastroenterol. 2015;15:138.CrossRefGoogle Scholar
  63. 63.
    Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018;18:1206–1213.CrossRefGoogle Scholar
  64. 64.
    Kwon S, Jeon JS, Ahn C, Sung JS, Choi I. Rapamycin regulates the proliferation of Huh7, a hepatocellular carcinoma cell line, by up-regulating p53 expression. Biochem Biophys Res Commun. 2016;479:74–79.CrossRefGoogle Scholar
  65. 65.
    Wang Z, Zhou J, Fan J, et al. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135:715–722.CrossRefGoogle Scholar
  66. 66.
    Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transplant. 2004;10:1301–1311.CrossRefGoogle Scholar
  67. 67.
    Geissler EK, Schnitzbauer AA, Zulke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016;100:116–125.CrossRefGoogle Scholar
  68. 68.
    Ferreiro AO, Vazquez-Millan MA, Lopez FS, Gutierrez MG, Diaz SP, Patino MJ. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series. Transplant Proc. 2014;46:3496–3501.CrossRefGoogle Scholar
  69. 69.
    Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–1354.CrossRefGoogle Scholar
  70. 70.
    Welker MW, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation—an emerging clinical challenge. Transplant Int. 2013;26:109–118.CrossRefGoogle Scholar
  71. 71.
    Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transplant. 2004;10:534–540.CrossRefGoogle Scholar
  72. 72.
    Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. 1999;17:324–331.CrossRefGoogle Scholar
  73. 73.
    Fernandez-Sevilla E, Allard MA, Selten J, et al. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection? Liver Transplant. 2017;23:440–447.CrossRefGoogle Scholar
  74. 74.
    Sapisochin G, Goldaracena N, Astete S, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large euro-american series. Ann Surg Oncol. 2015;22:2286–2294.CrossRefGoogle Scholar
  75. 75.
    Toso C, Cader S, Mentha-Dugerdil A, et al. Factors predicting survival after post-transplant hepatocellular carcinoma recurrence. J Hepatobiliary Pancreat Sci. 2013;20:342–347.CrossRefGoogle Scholar
  76. 76.
    Valdivieso A, Bustamante J, Gastaca M, et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc. 2010;42:660–662.CrossRefGoogle Scholar
  77. 77.
    Kim R, El-Gazzaz G, Tan A, et al. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology. 2010;79:62–66.CrossRefGoogle Scholar
  78. 78.
    Martin RC 2nd, Bruenderman E, Cohn A, et al. Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: observations from a US regional analysis of the GIDEON registry. Am J Surg. 2017;213:688–695.CrossRefGoogle Scholar
  79. 79.
    de’Angelis N, Landi F, Nencioni M, et al. Role of sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation. Prog Transplant. 2016;26:348–355.CrossRefGoogle Scholar
  80. 80.
    El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502.CrossRefGoogle Scholar
  81. 81.
    Friend BD, Venick RS, McDiarmid SV, et al. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma. Pediatr Blood Cancer. 2017;64:e26682.CrossRefGoogle Scholar
  82. 82.
    Gassmann D, Weiler S, Mertens JC, et al. Liver allograft failure after nivolumab treatment-a case report with systematic literature research. Transplant Direct. 2018;4:e376.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Trevor W. Reichman
    • 1
    Email author
  • Chandra S. Bhati
    • 1
  • Narendra R. Battula
    • 2
  1. 1.Division of Transplant Surgery, Department of SurgeryVirginia Commonwealth UniversityRichmondUSA
  2. 2.Division of Transplantation and Hepatobiliary SurgeryUniversity of FloridaGainesvilleUSA

Personalised recommendations